Clinical trial · Observational
COVID-19 Infection and Multiple Myeloma
COVID-19 INFECTION IN MULTIPLE MYELOMA PATIENTS: AN EUROPEAN OBSERVATIONAL STUDY
NCT04492371CI-TRIAL-00074691EMN-COVIDcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Collect in an observational study the outcomes of COVID19 infection in MM patients across Europe.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Corona Virus Infection | — | UNRESOLVED | — |
| Covid19 | — | UNRESOLVED | — |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (7)
- measure
- Nature of COVID19
- timeFrame
- 1 years
- description
- The duration of infection.
- measure
- Costs related to COVID-19
- timeFrame
- 1 years
- description
- Costs related to Covid in terms of health resource needs.
- measure
- Systemic anti-cancer therapy subgroup
- timeFrame
- 1 years
- description
- Number of infection recovery for each systemic anti-cancer subgroup.
- measure
- Laboratory values collected at hospitalization
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Multiple Myeloma patients * COVID-19 infection
References
Publications (0)
Data not yet available
No reference posted for this study.